Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC
Enzalutamide + ADT showed better efficacy than darolutamide + ADT for treatment of patients with mHSPC. These findings can help inform treatment decisions in clinical practice.
Authors
- Andrew J. Armstrong (ORCID: https://orcid.org/0000-0001-7012-1754)
- Arun Azad (ORCID: https://orcid.org/0000-0001-7350-5622)
- Ana Moura (ORCID: https://orcid.org/0000-0002-6323-9073)
- Hemant Singh Bhadauria
- Bhavik J. Pandya
- Arijit Ganguli (ORCID: https://orcid.org/0009-0000-2569-2734)
- Vagia Daki
Institutions
- The University of Melbourne (AU)
- Duke University (US)
- Peter MacCallum Cancer Centre (AU)
- IQVIA (United Kingdom) (GB)
- Astellas Pharma (United States) (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1080/14796694.2025.2526324
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52